PHAT - Phathom Pharmaceuticals completes enrollment in Phase 3 H. pylori trial

Phathom Pharmaceuticals (PHAT) has completed patient enrollment in PHALCON-HP, a pivotal Phase 3 clinical trial of vonoprazan and vonoprazan for the eradication of H. pylori infection.PHALCON-HP is a randomized, multicenter, Phase 3 trial that has enrolled over 1,000 patients with H. pylori infection.Phathom continues to expect topline results from the study in Q2 2021.PHALCON-HP is one of two Phase 3 trials evaluating vonoprazan in gastrointestinal diseases.And the second trial, PHALCON-EE, is a randomized, double-blind, two-phase, multicenter trial evaluating vonoprazan in the treatment of erosive esophagitis.

For further details see:

Phathom Pharmaceuticals completes enrollment in Phase 3 H. pylori trial